open access

Vol 9, No 2 (2006)
Published online: 2006-06-21
Submitted: 2012-01-23
Get Citation

Treatment of local and regional recurrences of differentiated thyroid cancer by radio-guided surgery with Iodine-131

Massimo Salvatori et al.
Nucl. Med. Rev 2006;9(2):119-124.

open access

Vol 9, No 2 (2006)
Published online: 2006-06-21
Submitted: 2012-01-23

Abstract


BACKGROUND/MATERIAL AND METHODS: The aim of this study was to assess the reliability of radioiodine (131I) and a gamma probe for radio-guided surgery (RGS) to detect and radically dissect lymph node recurrence (LNR) in 15 patients with differentiated thyroid cancer (DTC). The major inclusion criterion was the presence of a radioiodine-positive LNR after previous total thyroidectomy and at least two ineffective 131I treatments. The protocol was designed as follows: Day 0 - all patients were hospitalized and received 3.7 GBq of 131 I while clinically hypothyroid. Day 3 - pre-surgery whole-body scan with a therapeutic 131I dose (TxWBS) was acquired. Day 5 - neck surgery using a gamma probe (Navigator GPS, AutoSuture, Italy), recording the absolute counts and the lesion/background (L/B) counts ratio was performed. Day 7 - post-surgery TxWBS was performed using the remaining radioactivity.
RESULTS AND CONCLUSIONS: This protocol permitted us to identify neoplastic foci with high sensitivity and specificity, enabling us to remove lymph node metastases resistant to radioiodine therapy in a single session. The protocol also allowed detection of some additional tumoural foci in sclerotic areas or behind vascular structures that were not seen at the pre-surgery TxWBS evaluation.

Abstract


BACKGROUND/MATERIAL AND METHODS: The aim of this study was to assess the reliability of radioiodine (131I) and a gamma probe for radio-guided surgery (RGS) to detect and radically dissect lymph node recurrence (LNR) in 15 patients with differentiated thyroid cancer (DTC). The major inclusion criterion was the presence of a radioiodine-positive LNR after previous total thyroidectomy and at least two ineffective 131I treatments. The protocol was designed as follows: Day 0 - all patients were hospitalized and received 3.7 GBq of 131 I while clinically hypothyroid. Day 3 - pre-surgery whole-body scan with a therapeutic 131I dose (TxWBS) was acquired. Day 5 - neck surgery using a gamma probe (Navigator GPS, AutoSuture, Italy), recording the absolute counts and the lesion/background (L/B) counts ratio was performed. Day 7 - post-surgery TxWBS was performed using the remaining radioactivity.
RESULTS AND CONCLUSIONS: This protocol permitted us to identify neoplastic foci with high sensitivity and specificity, enabling us to remove lymph node metastases resistant to radioiodine therapy in a single session. The protocol also allowed detection of some additional tumoural foci in sclerotic areas or behind vascular structures that were not seen at the pre-surgery TxWBS evaluation.
Get Citation

Keywords

radio-guided surgery; thyroid cancer; local regional recurrences; radioiodine

About this article
Title

Treatment of local and regional recurrences of differentiated thyroid cancer by radio-guided surgery with Iodine-131

Journal

Nuclear Medicine Review

Issue

Vol 9, No 2 (2006)

Pages

119-124

Published online

2006-06-21

Bibliographic record

Nucl. Med. Rev 2006;9(2):119-124.

Keywords

radio-guided surgery
thyroid cancer
local regional recurrences
radioiodine

Authors

Massimo Salvatori et al.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl